Summary
We recommend a moderate overweight position (~15% allocation) in the SPDR S&P Aerospace & Defense ETF (XAR). The fund offers diversified exposure to U.S. defense and aerospace with strong 3–5 year growth drivers. After a 50%+ rally in the past year, valuations are now near fair value, so near-term upside is more modest. However, secular tailwinds (rising defense budgets, commercial aerospace recovery) support double-digit earnings growth. We see further 12M upside of ~10–15% under a normalizing macro regime, with 3Y total return potential in the 30–40% range. Position sizing should be capped at ~15–20% (high conviction) given recent volatility and geopolitical risk.
Top 5 Takeaways
- Macro Regime – Late-Cycle but Supportive: Our regime detector classifies the current environment as “Rate-Spike/Normal” (high rates without recession). Yield curves have uninverted and PMI hovers ~49–51 (borderline contraction). This favors quality defensive stocks. We overweight Quality and Safety factors, given defense’s stable cash flows, while moderating Value and Growth weights (to reduce collinearity). Technical momentum remains strong, boosting the Momentum factor weight.
- Peer Performance: XAR’s equal-weight approach has outperformed larger-cap peers. XAR is +50% over the past year vs. ~+41% for iShares ITA and +38% for Invesco PPA. Its mid-cap tilt (drones, space) captured innovation trends. Expense ratio is a low 0.35% (cheaper than ITA’s 0.40% and PPA’s 0.57%). However, XAR’s P/E (~36x) is slightly higher than ITA’s (~36x) and PPA’s (~30x), reflecting growth exposure.
- ESG & Controversies: The defense sector carries high ESG risk – XAR ranks in the worst 10% for sustainability. Many holdings are involved in controversial weapons (e.g. cluster munitions, landmines). Investors must weigh ethical considerations; some ESG funds avoid arms makers. There are also political risks around defense spending (though bipartisan support remains strong). We flag a controversy risk but note that defense firms are emphasizing “ethical” tech (cybersecurity, precision weapons) to mitigate concerns.
- 12M Bullish Thesis: Geopolitical tensions (Europe, Middle East, Indo-Pacific) continue to drive defense outlays. U.S. defense budget proposals near $1 trillion are boosting contractors. Commercial aerospace is rebounding with record order backlogs. XAR’s mid-cap holdings (drones, space tech) stand to gain as warfare evolves (e.g. drone warfare, private space). We expect high-single-digit to low-double-digit 12M returns (~10%), assuming no recession. A bull-case (no rate shocks, new conflict-driven demand) could push ~15–20% upside.
- 3Y Mid-Term Outlook: Over 3 years, we project total returns ~30–40% (CAGR ~10% p.a.), supported by double-digit industry growth. Rising defense budgets (2024 global spending hit a record $2.72 T) and surging aerospace demand (passenger travel recovery) underpin earnings growth ~11%. Free cash flows should expand as major programs (fighters, hypersonics, space systems) scale up. Barring an extreme macro shock or peace dividend scenario, XAR’s diversified portfolio is poised for continued outperformance vs. the broader market (historically +5%/yr over S&P 500).
Why We’re Bullish – 12 Month Thesis
Robust Demand & Backlog: Defense contractors are enjoying record backlogs and profits, indicating robust demand into 2025. Geopolitical catalysts abound – NATO rearmament, Indo-Pacific tensions, and a recent Middle East flare-up. As one analyst notes, “Aerospace & defense revenues are at record highs… robust demand [is] likely to continue”. U.S. FY25 defense spending is up ~5%, prioritizing next-gen tech (hypersonics, AI-enabled drones). This benefits XAR’s holdings like Kratos Defense (unmanned systems) and AeroVironment (drones). Meanwhile, commercial aerospace (20–30% of XAR’s exposure) is in cyclical upswing – global air travel is rising and airlines are ordering new jets, driving demand for TransDigm and Howmet parts.
Mid-Cap Edge & Innovation: XAR’s equal-weight methodology tilts toward mid-caps driving innovation. For example, AeroVironment (AVAV) and Rocket Lab are top holdings (~4% each), giving exposure to drones and space launches that mega-cap weighted ETFs underplay. The sector is “evolving, with private companies and drone warfare driving innovation”, and XAR captures these trends. Notably, Axon Enterprise (Taser and police tech) and Rocket Lab are among XAR’s top holdings – companies at the cutting edge of defense tech. This positioning paid off: XAR has outperformed the S&P by ~20% since mid-2023. We expect continued alpha generation as defense technology accelerates (autonomous systems, cybersecurity).
Resilience in Slowdowns: Should the economy slow, defense spending is largely non-cyclical. Many XAR components derive the bulk of revenue from government contracts, buffered from consumer sentiment. Even in a mild recession scenario, we expect stable cash flows – the DoD’s $849 B FY25 budget underscores bipartisan support. During past downturns, defense stocks often outperformed due to their steady revenues (e.g. 2020’s pandemic saw defense names fall less and recover faster than the broad market). Moreover, with the yield curve normalizing and no imminent recession signal, the macro backdrop should allow the sector to continue re-rating on earnings growth. Consensus 3–5y EPS CAGR ~11% for XAR’s holdings suggests robust intrinsic momentum.
Mid-Term Outlook – 3 Year View
Over a 2–3 year horizon, the investment case remains strong. Aerospace & defense are in a secular uptrend – global military spending is rising at ~4–5% CAGR (faster in NATO countries), and commercial aerospace is recovering from depressed levels toward new highs by 2026. A recent S&P Global outlook expects many defense firms to benefit from “robust demand from both commercial and defense sides” in coming years. We anticipate XAR’s earnings will compound double-digit, driven by:
- Modernization Cycles: The U.S. and allies are upgrading arsenals (e.g. hypersonic missiles, 5th-gen fighters, naval ships). Programs like the B-21 stealth bomber, new NATO tank and missile defense systems all flow into revenues for Northrop Grumman, RTX Corp, Lockheed Martin, etc. XAR holds all these key primes. As governments confront “peer competition” (China/Russia), modernization spend should accelerate.
- Commercial Aerospace Boom: Boeing and Airbus have massive order backlogs (8–10 years’ worth of production). XAR’s suppliers like General Dynamics (business jets via Gulfstream) and HEICO (aircraft components) benefit from this multi-year delivery cycle. By 2025–2027, global air traffic is projected to grow ~5% CAGR, bolstering demand for new aircraft and aftermarket parts. This underpins a long runway for aerospace earnings.
- Cash Flow & Capital Returns: Many XAR companies generate solid free cash, supporting dividends and buybacks. General Dynamics yields ~2.2% and boasts 32 consecutive years of dividend hikes, exemplifying sector quality. We expect dividend growth (low starting yield ~0.5% for XAR) to contribute a small but steady portion of total returns. Importantly, defense firms have investment-grade balance sheets and manageable debt (avg Debt/Capital well within safe ranges), reducing risk over a multi-year period.
Our base-case 3Y scenario (assuming no global recession or major peace dividend event) sees XAR delivering high-20s to low-30s percent cumulative price appreciation (≈9–10% CAGR) plus ~1–2% in dividends – roughly 10–12% annual total returns. In a bull-case (continued global tensions, tech breakthroughs, and some valuation expansion), returns could approach 15% annualized. The bear-case (sharp recession or budget cuts) is more muted: we estimate ~4–5% annual returns even if valuations compress, given the sector’s revenue resilience and likely rotation into defense as a “safe” play in geopolitically uncertain times.
Risk Flags to Watch
Despite our constructive view, we flag several risks:
- Defense Budget Cuts / Politics: A surprise political shift toward fiscal restraint or peace treaties could dampen U.S. defense spending. For instance, if conflict risks abate (e.g. a Ukraine peace deal), defense budgets might face cuts. A recent proposal to trim military spending could resurface, though current bipartisan consensus for modernization is strong. Still, investors should monitor Washington debates – defense stocks dipped on past budget cut rumors.
- Valuation & Rate Sensitivity: After a 50% rally, valuations are elevated (XAR’s P/E ~36x vs S&P ~20x). If interest rates spike further or stay “higher for longer”, high-multiple stocks could de-rate. XAR’s Beta ~1.1 means it can be a bit more volatile than the market. A sharp rise in the 10-year yield or credit spreads could pressure equities broadly, including aerospace/defense. However, XAR’s cash-flow stability provides some cushion relative to more speculative sectors.
- Execution & Program Risks: Big defense projects come with execution risk – e.g. Lockheed’s F-35 fighter has faced cost overruns and delays. Similarly, Boeing (a holding via ITA overlap) is still rebuilding trust after the 737 MAX crisis. Any major program setback or defense contractor scandal (e.g. quality issues, cyber breach) could hurt sector sentiment. So far, 2024–2025 contract execution has been solid, but it’s a point to watch.
- Geopolitical Wildcards: Ironically, while conflict escalation boosts defense demand, an unexpected end to major conflicts could stall the defense rally. For example, “peace prospects in Ukraine” earlier in 2025 had tempered defense stock momentum. Conversely, an extreme event (e.g. direct superpower conflict) could initially spook markets broadly. Also, export risks exist: if U.S. defense exports face political hurdles or foreign budget strains, companies like General Dynamics (tanks, ships) and Raytheon (RTX) (missiles) could see order slowdowns.
- ESG and Bans: Growing ESG mandates might restrict investor capital to defense stocks, as many funds exclude “controversial weapons” makers. Some European investors have divested defense holdings for this reason. While this hasn’t stopped stock appreciation so far (given other buyers), a significant shift in ESG regulation (e.g. EU taxonomy penalizing defense) is a longer-term overhang.
Overall, these risks are worth monitoring but are mitigated by the sector’s fundamentals – defense demand tends not to disappear even in budget trim scenarios (it’s just deferred), and valuations, while not cheap, are supported by earnings growth and fair value alignment. We do not see red flags that would derail the multi-year thesis, but volatility around headlines is likely. We’d use any material pullback (10%+ drawdowns) as an opportunity to accumulate XAR, given secular tailwinds.
Investment Thesis & Valuation – XAR vs Peers
XAR provides a one-stop, equal-weighted exposure to U.S. Aerospace & Defense – spanning missiles, aircraft, shipbuilding, satellites, and emerging tech. Its top holdings (40 stocks total) include Huntington Ingalls (ships), Textron (aircraft), General Dynamics (tanks, biz jets), HEICO (parts), and innovative smaller firms like Kratos and Rocket Lab. Unlike the cap-weighted iShares ITA (where giants like Boeing and Lockheed dominate ~20%+), XAR caps concentration – its largest holding ~4%. This unconcentrated industry exposure is a key advantage noted by State Street. It means mid-cap growth contributors can move the needle, as we saw with XAR’s outperformance.
Peer Comparison: In the table below, we compare XAR to ITA and PPA – the closest Aerospace & Defense ETF peers:
| ETF (Ticker) | AUM | Expense | 1Y Total Return | Top Holdings (Weight) | P/E (TTM) | Yield | Approach |
|---|---|---|---|---|---|---|---|
| SPDR S&P Aero/Def (XAR) | $3.6 B | 0.35% | +50.1% | AVAV, HII, KTOS (~4% each) | ~36.8x | 0.53% | Equal-weight (40 stocks) |
| iShares US Aero/Def (ITA) | $7.5 B | 0.40% | +41.2% | BA 20%, RTX 18%, LMT 16% (cap-weight) | ~36x | 0.69% | Cap-weight (33 stocks) |
| Invesco Aero/Def (PPA) | $5.3 B | 0.57% | +38.4% | LMT 6%, RTX 6%, GD 5%, BA 5% | ~30.5x | 0.47% | Modified equal-weight (58) |
Sources: Fund sponsor data and Yahoo/StockAnalysis as of Jul 2025.
XAR stands out for its low fees (cheapest of the three) and highest 1Y return. Its equal-weight strategy resulted in larger allocations to 2023’s high-flyers (e.g. small drone stocks) – fueling the performance edge. By contrast, ITA and PPA have more mega-cap exposure; notably, ITA’s top two (Boeing, RTX) make up >30% of assets, which dragged in 2022 but helped in early 2023, hence ITA’s strong but slightly lower 1Y return. PPA holds a broader basket (58 names) including some defense tech and international firms (via the SPADE index). PPA’s P/E is lower (~30x), suggesting it tilts to value names or lower growth. Indeed, PPA’s long-term return (since inception ~13% CAGR) is a bit lower than XAR’s ~17.8%, possibly due to that more value-oriented mix.
From a valuation perspective, XAR now trades near our calculated fair value. Using a dual-stage DCF (see below), we estimate XAR’s NAV at ~$210, essentially inline with the market price (no big discount). This assumes ~10% EPS growth for 5 years then ~3% terminal growth, with WACC ~8%. Notably, in Dec 2024 an analyst rated XAR a “Buy… poised for strong returns in 2025 due to robust industry growth”, citing that the forward P/E ~25 was in line with the 10-year average, implying fair value. Our analysis agrees: XAR isn’t “cheap” after the rally, but nor is it excessive given growth. The PEG ratio (P/E to long-term growth) is ~2.3, a bit higher than the S&P500 (~1.6), indicating slightly rich valuation for growth – but understandable given defense’s stability premium.
Finally, position sizing: We suggest a 15% allocation (out of an equity portfolio) for XAR for those seeking overweight exposure. This reflects high conviction but acknowledges volatility. XAR cleared our “Ultra Value” buy criteria earlier (it was >30% undervalued last year), but at current prices it’s a normal Buy rather than screaming bargain (price ≈ fair value). Should it pull back into the “Strong Buy zone” (~30% below fair value, i.e. under $150), we’d advocate adding aggressively.
Monte Carlo Simulation – 12M Risk/Reward
Monte Carlo simulation of 10,000 trials for XAR’s 12-month total return. The distribution is roughly log-normal, centered around a high-single-digit return. We derive a 5% Value-at-Risk (VaR) of about –20% (red dashed line), meaning there’s a 1-in-20 chance XAR falls more than 20% in the next year. The 1% tail VaR is –30%. The expected shortfall (average of worst 5% outcomes) is –26%【46†】. Conversely, upside in the bullish tail shows 5% probability of >+30% gain. Mean (+9%) and median (+8%) expected returns are in the upper-single digits, aligning with our base-case. Notably, XAR’s volatility (~22% annual) is higher than the market’s (~15%), reflecting its beta ~1.1. “Years to double” median ~6–7 years, i.e. a ~$208 investment could reasonably take ~6 years to reach $416 given ~11% expected CAGR.
Source: Simulated price paths using assumed μ=12%, σ=20%. VaR/ES calculated from distribution of outcomes.
Bayesian Scenario Fan Chart – Price Forecast
Projected price range for XAR over the next 3 years under Bull, Base, and Bear scenarios, weighted by our Bayesian macro regime probabilities. The dark blue line is the median expectation (base case), reaching around $280 by mid-2028 (≈35% above current). The shaded bands show the 50% (deep blue), 75% (medium), and 95% (light) confidence intervals. In the bull case (upper bound of 95% band), XAR could approach $550+ in 3 years (implying double from $208) if growth far exceeds expectations (e.g. prolonged geopolitical crises and tech breakthroughs). The bear case (lower 95% bound) has XAR around $140–$150 at 3Y – roughly flat to slightly down total return, representing a mild recession scenario with valuation compression. Notably, even the bear case band is relatively flat, underscoring that defense earnings rarely collapse. Our base case (central band) has XAR in the mid-$200s within 2 years and rising steadily. These projections assume a “normal” regime (no major recession), adjusted for probabilities of a late-2025 downturn (we assign ~25% chance of recession, 15% of rate shock, which skew the lower bands).
Source: Bayesian model conditioning bull/base/bear on macro regime (Normal vs Recession vs Rate Spike). Bands derived from Monte Carlo path percentiles【49†】.
DCF Valuation & Sensitivity Analysis
We performed a discounted cash flow (DCF) valuation on XAR’s portfolio cash flows. Given the ETF structure, we aggregated an effective FCF yield ~2.7% and growth ~10–11%, discounting at 8%. This yielded an intrinsic value around $210/unit, essentially equal to the NAV ($208.59 as of July 3, 2025). Conclusion: XAR is trading at fair value – the strong recent gains have erased the deep undervaluation from 2024. That said, fair value is expected to grow as earnings compound; our DCF implies a 3-year forward NAV in the $270–280 range (consistent with the fan chart median).
Key valuation inputs include a WACC of ~8% (reflecting a beta ~1.1 and 4% risk-free + 5% equity risk premium) and a terminal growth of 3%. We assume segment operating margins ~12% and reinvestment (capex) ~4% of revenue, inline with industry norms. State Street’s 3–5y EPS growth forecast of ~11% was used for the initial growth stage.
Tornado Sensitivity: We stress-tested the DCF for changes in capex and margins, two critical drivers. The tornado chart below shows the impact on fair value from varying these assumptions:
Tornado chart – DCF fair value sensitivity. Each bar shows the percentage change in intrinsic value from the base case (vertical line = 0%). Operating margin ±3 percentage points (from 12% base) swings fair value by nearly ±43% (the biggest factor) – e.g. if net margins improved to 15%, our fair value would jump ~+43% to ~$300, whereas at 9% margins it’d drop ~–43% to ~$120. Capex ±25% (as % of rev) moves value by ~±18%. We also tested WACC ±1% (not shown fully): +1% WACC lowers value ~17%, –1% raises it ~26%. These sensitivities highlight that profitability is the most crucial variable for defense valuations – modest margin expansion (via operating leverage or efficiency) would greatly boost XAR’s worth. Conversely, a margin squeeze (due to cost inflation or program issues) is a notable risk to valuation. Our base-case assumes stable margins; many XAR firms actually have room to improve margins as supply chain issues ease. Capex variability has a smaller effect, since defense firms have moderate capital expenditure needs.
Source: Analyst DCF model. Base fair value ≈ $210. Bars reflect scenario values relative to base (0% line).
Technical Snapshot – Momentum & 200-Day Breakout
*XAR price chart vs. its 200-day moving average (MA). After languishing in early 2024, XAR broke above its 200-day MA decisively last fall amid rising geopolitical tensions (green shaded area shows price > MA). The fund hit a 52-week low around $137 in mid-2024, then rallied sharply to new highs (~$211 in Jul 2025). It is currently ~22% above its 200-day MA – a technically bullish sign, albeit extended. Short-term momentum is strong: the 14-day RSI ~69 is just below overbought (70). We also note a series of higher lows and higher highs since last October, confirming an uptrend. The recent pullback from $211 to ~$206 was minor, and XAR found support near its 20-day MA.
From here, a period of consolidation would be healthy – XAR’s RSI flirting with 70 suggests a pause/correction could occur. Key support levels: the 50-day MA (~10% below current) and the 200-day MA (around $170) – that latter coincides with a prior breakout zone. Key resistance: the recent high at $211. A push above $211 on volume would signal another leg up. If broader markets remain risk-on, XAR’s relative strength could continue – it has outperformed the S&P 500 by ~20% since mid-2023. Overall, technicals paint a positive picture but with near-term overbought conditions – new entrants might wait for dips toward $190 or the 50-day MA to improve risk/reward.*
Conclusion & Recommendation
Bottom Line: XAR offers a compelling blend of growth and defense. The sector’s fundamentals – unprecedented defense spending, urgent modernization, and recovering aerospace – support above-market earnings expansion for the next several years. XAR’s equal-weight design further amplifies exposure to high-growth niches (drones, space) that are reshaping modern warfare. Our multi-factor model rates XAR a “Buy” (not ultra-cheap, but a high-quality play). We suggest initiating or adding to positions on any weakness, with an eye on the $180–190 level as an attractive entry (minor corrections).
Given the strong run, we wouldn’t be surprised by some short-term volatility or sector rotation – but we would view that as transient. The risk/reward remains favorable: even under conservative scenarios, XAR should deliver solid mid-teens total returns over 3 years, while providing portfolio defense (pun intended) against geopolitical shocks. For investors seeking to fortify their portfolios with industrial and defense exposure, XAR is a top choice. It’s also suitable as a tactical holding if one anticipates rising global tensions (as recent events have shown, defense stocks can “often be the best offense” in uncertain times).
Recommendation: Buy on dips for long-term accumulation. Maintain a moderate overweight stance. Our 12-month forward price target is ~$230 (assuming ~10% earnings growth and a fair ~20x cash flow multiple) – implying modest upside. Over 3+ years, we expect XAR to outperform broad equities on a risk-adjusted basis, with a potential total return of 30–40%. Keep an eye on headline risks (budget news, peace talks) for opportunistic add points. Barring a dramatic macro downturn, XAR should continue to be a high-conviction holding in an equity portfolio.
Master Metrics Snapshot
| Metric | Value/Status |
|---|---|
| Current Price (NAV) | $208.59 (Jul 03 ’25) |
| Fair Value (DCF) | ~$210 (≈ in line with market) |
| Discount/Premium vs. FV | ~0% (Fairly valued) |
| Strong-Buy Zone | < ~$146 (≃30% below FV) |
| 12M Total Return (TTM) | +50.1% (including dividends) |
| YTD Total Return | +26.0% |
| 3-Year Total Return | +108.3% (cumulative) |
| Volatility (1Y) | ~22% (std. dev. annualized) |
| Beta (vs S&P500) | 1.11 (5Y monthly) |
| Sharpe (Est. 12M) | ~0.5 (9%/18% vol, rough estimate) |
| TTM P/E Ratio | 36.8× |
| Forward P/E (Est.) | ~25× (FactSet consensus) |
| PEG Ratio | ~2.3 (36.8x / 15.8%*. see note) |
| EPS Growth (3–5 Yr) | ~11.0% CAGR (consensus) |
| Dividend Yield (TTM) | 0.53% |
| Expense Ratio | 0.35% p.a. |
| Quality Score | High (strong finances, e.g. GD’s 32-yr div streak) |
| Momentum Score | Very Strong (1Y outperformance +20% vs S&P) |
| Safety Score | Moderate (low earnings volatility, but stock beta >1) |
| ESG Risk | High (arms exposure; “Worst 10%” sustainability) |
| Controversy Flag | Yes – Involved in controversial weapons |
Note: PEG uses 15.8% as blended LT growth (11% EPS + ~4.8% dividend & buyback yield equivalent). Despite high PEG, defense stability justifies some premium.
📚 References
- State Street Global Advisors – SPDR S&P Aerospace & Defense ETF (Fund overview & key facts)
- StockAnalysis – XAR ETF Profile (holdings, performance, P/E, yield, etc.)
- Yahoo Finance / Finviz – ITA vs PPA vs XAR Returns and Valuations (Expense ratios, AUM, performance)
- StockAnalysis News – “XAR: New Trends in Aerospace & Defense… Drive This ETF” (SA article summary)
- StockAnalysis News – “XAR: Often The Best Offense Is A Great Defense ETF” (performance vs S&P, sector evolution)
- MLQ.ai Digest – Highlights from SA articles (XAR) – Growth outlook, fair P/E ~25, State Street LT EPS ~11%
- Seeking Alpha – “Iran Escalation Could Rally U.S. Defense Stocks – XAR Top Choice” (Middle East tensions, budget boost)
- MarketWatch – “A&D ETFs beat S&P 500 as Middle East fears intensify” (sector surge in late 2024)
- PwC 2025 Midyear Outlook – A&D innovation and performance (sector demand drivers)
- Ainvest (Isaac Lane) – “Fortifying Portfolios with Defense Industrials” (U.S. defense growth forecast, DoD priorities, ESG angles)
- S&P Global Ratings Outlook 2025 – “Industry Credit Outlook: Aerospace & Defense” (commercial & defense demand)
- Finviz – XAR Snapshot (Beta, RSI, 52W high/low, YTD return as of July 3 ’25)
- Nasdaq/ETF.com – “Right Sector, Wrong Fund” (XAR vs PPA/SHLD performance commentary, Oct 2024)
- Zacks – Multiple ETF News (Half-year 2025 momentum, “Should You Invest in XAR/PPA?”, etc.)
- Advisor Perspectives – Yield Curve Update (June 27 ’25) (10Y at 4.39%, 2Y 3.3% – curve uninverted)
- ISM PMI Report (June 2025) – Manufacturing ~49.0 (slight contraction)
- MarketBeat – XAR 200-day MA Cross (XAR crossed above 200d MA by mid-2025) (context)
- Vulcan Mk5 Model Description – (Details on factor weights, “Ultra Value” 30% discount rule, etc.)
Vulcan Stock Research 
Leave a comment